In summary, our study suggests that in patients with HCC, miR-216b, which could be transcriptionally reduced by HBx, functions as a tumor suppressor by targeting IGF2BP2 and subsequently suppressing the downstream IGF2, AKT/mTOR and MAPK/ERK signaling pathways. This evidence concerns the gene IGF2BP2 and neoplasm.